Загрузка...

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women

CONTEXT: In the Women's Health Initiative estrogen plus progestin trial, after mean (SD) intervention of 5.6 (1.3) years (range 3.7 to 8.6 years) and mean follow-up of 7.9 (1.4) years, breast cancer incidence was increased by combined hormone therapy. However, breast cancer mortality results ha...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA
Главные авторы: Chlebowski, Rowan T., Anderson, Garnet L., Gass, Margery, Lane, Dorothy S., Aragaki, Aaron K., Kuller, Lewis H., Manson, JoAnn E., Stefanick, Marcia L., Ockene, Judith, Sarto, Gloria E., MD, Karen C. Johnson, Wactawski-Wende, Jean, Ravdin, Peter M., Schenken, Robert, Hendrix, Susan L., Rajkovic, Aleksandar, Rohan, Thomas E., Yasmeen, Shagufta, Prentice, Ross L.
Формат: Artigo
Язык:Inglês
Опубликовано: 2010
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5142300/
https://ncbi.nlm.nih.gov/pubmed/20959578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2010.1500
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!